Related Experiment Video
Updated: Jul 25, 2026
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
CD47 as a biomarker for ovarian cancer: prospects and challenges
Xiaorui Cheng1, Chi Yan1, Jinjin Zhao1
1Clinical Laboratory, The First Affiliated Hospital of Xinxiang Medical University, No. 88, Jiankang Road, Weihui， Xinxiang, Henan 453100, China.
Abstract:
Ovarian cancer is one of the deadliest malignant tumors in the female reproductive system. Currently, an efficient approach for the early detection and reliable prognosis assessment of ovarian cancer remains unavailable, which is still a difficult problem worthy of study. In recent years, cluster of differentiation 47 (CD47) has attracted attention in tumor biology, it provides new possibilities for solving ovarian cancer problems. Although CD47 still has many challenges in clinical practice, such as standardization of detection methods and joint application strategies with other biomarkers, it still shows its potential as a biomarker. This article reviews some serum biomarkers in ovarian cancer, the biological characteristics of CD47, prospects and challenges faced as a biomarker in ovarian cancer, aiming to provide a comprehensive analysis of CD47 application in ovarian cancer.
Insights
Early ovarian cancer detection remains a challenge. Cluster of differentiation 47 (CD47) shows potential as a biomarker for ovarian cancer, despite facing clinical hurdles.
Area of Science:
- Oncology
- Biomarker Discovery
- Molecular Biology
Background:
- Ovarian cancer is a leading cause of cancer death in women.
- Effective early detection and prognosis methods for ovarian cancer are lacking.
- Cluster of differentiation 47 (CD47) has emerged as a significant factor in tumor biology.
Purpose of the Study:
- To review existing serum biomarkers for ovarian cancer.
- To explore the biological characteristics of CD47 in ovarian cancer.
- To analyze the potential, prospects, and challenges of CD47 as an ovarian cancer biomarker.
Main Methods:
- Literature review of ovarian cancer serum biomarkers.
- Analysis of CD47's biological roles and significance in cancer.
- Evaluation of CD47's utility and limitations as a diagnostic and prognostic marker.
Main Results:
- CD47 presents new possibilities for addressing ovarian cancer challenges.
- CD47 demonstrates potential as a valuable biomarker in ovarian cancer.
- Challenges include standardizing detection and integrating CD47 with other biomarkers.
Conclusions:
- CD47 holds promise as a biomarker for ovarian cancer.
- Further research is needed to overcome clinical application challenges.
- Comprehensive analysis supports CD47's potential role in ovarian cancer management.
